Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP07786239A	2012-10-29	Actavis Group ehf	Opposition rejected
EP07786239A	2011-09-15	Antares Pharma, Inc.	Opposition rejected

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8664231	July, 2016	FWD Entered	MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH	Koios Pharmaceuticals LLC
US8664231	February, 2016	Terminated-Settled	MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH	Frontier Therapeutics, LLC
US8664231	July, 2014	Terminated-Settled	Medac Gesellschaft Fur Klinische	Antares Pharma, Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8664231	MEDEXUS	Concentrated methotrexate solutions	Jun, 2029 (5 years from now)

Rasuvo is owned by Medexus.

Rasuvo contains Methotrexate.

Rasuvo has a total of 1 drug patent out of which 0 drug patents have expired.

Rasuvo was authorised for market use on 10 July, 2014.

Rasuvo is available in solution;subcutaneous dosage forms.

Rasuvo can be used as subcutaneous injection of methotrexate.

The generics of Rasuvo are possible to be released after 01 June, 2029.

Market Authorisation Date: 10 July, 2014

Treatment: Subcutaneous injection of methotrexate

Dosage: SOLUTION;SUBCUTANEOUS

Rasuvo patents expiration